Invion Ltd. · ASX:IVX
Invion — Investor Presentation (April 2013)
18 slides from Invion's investor presentation, Apr 2, 2013
Slide 1: Invion Limited Investor Presentation
For personal use only Invion Limited (ASX:IVX) Clinical-stage drug development company targeting chronic inflammation Investor Presentation April | 2013
Slide 2: Disclaimer
For personal use only Disclaimer This presentation has been prepared by Invion Limited (Invion or the Company) solely for its use at presentations to be made by the Company. The information contained in this presentation is an overview and does not contain all information necessary to make investmen
Slide 3: Company Proposition
Company Proposition For personal use only 2 drug candidates 3 phase II clinical programs Large market opportunity Commercial precedent and data to support strategy Experienced management team Preclinical Phase I Phase II INV102 (nadolol) Chronic Bronchitis In patients undergoing smoking cessation (o
Slide 4: Company Snapshot
Company Snapshot For personal use only Corporate Strategy > Australian listed company (ASX:IVX) > Cost-effective development of mid-stage drug > Sector: Life Sciences (Biotechnology) assets to the point of commercial partnership > Activities: clinical-stage drug development Operations: Brisbane (AU)
Slide 5: Experienced leadership team
Experienced leadership team For personal use only Executive Directors Independent Directors William Garner, M.D., MD and CEO Ralph Craven, BE PhD FAICD FIEAust > Successful corporate founder and FIPENZ CPEng, Chairman of the Board executive. Roche, Founder of EGB > Respected member of international
Slide 6: Opportunity: growing inflammation market
For personal use only Opportunity: growing inflammation market INV102 (nadolol): asthma, chronic obstructive pulmonary disease (COPD) INV103 (ala-Cpn10): systemic lupus erythematosus (lupus)
Slide 7: INV102: add-on to existing therapies = safer, more effective
INV102: add-on to existing therapies = safer, more effective For personal use only > Asthma and COPD prescription drugs $34B > Advair Diskus ® (asthma and COPD) $8.1B > Singulair ® (asthma) $5.5B Respiratory world market $64.6B > Symbicort ® (asthma and COPD) $3.1B > FDA Black box warning on all Lon
Slide 8: INV103: potential new therapy in under-serviced lupus market
INV103: potential new therapy in under-serviced lupus market For personal use only > March 2011 FDA approved the first new drug for lupus in more than 50 years > Reflection of the complexity of the disease > Clear indication of a major unmet clinical need > Forecast: sales of over $4B in the US and
Slide 9: INV102 (nadolol)
For personal use only INV102 (nadolol) Using an existing drug to target inflammatory lung conditions
Slide 10: INV102 (nadolol): overview
INV102 (nadolol): overview For personal use only > Beta blocker > Current indications: high blood pressure, chest pain, migraine > Being repurposed to treat: inflammatory lung conditions Data to date > Preclinical data confirms nadolol as adrenergic inverse agonist > provides unique anti-inflammator
Slide 11: Medical, regulatory and commercial precedent
Medical, regulatory and commercial precedent For personal use only Precedent: Chronic Heart Failure (CHF) FROM TO CONTRAINDICATED STANDARD OF CARE Warning against use of After careful titration, beta blocker beta blockers in CHF for > 25 years. Carvedilol reduced mortality in Carvedilol annual sales
Slide 12: Airway healing: effect of oral INV102
Airway healing: effect of oral INV102 For personal use only Control lung tissue Lung tissue of ‘asthmatic’ mice: Lung tissue of ‘asthmatic’ mice epithelial cells have been converted treated with INV102 (nadolol) for 28 to mucus-producing goblet cells. No days: restored epithelium effect on alprenolo
Slide 13: Two phase II clinical programs
Two phase II clinical programs For personal use only Chronic bronchitis (smoking cessation) > Total treatment period less than 3 months > Target outcomes: increase smoking cessation, reduce airway inflammation, decrease peri-operative complications > Phase II data anticipated in 2013 calendar year >
Slide 14: INV103 (ala-Cpn10)
For personal use only INV103 (ala-Cpn10) Using a natural human protein to target autoimmune inflammation
Slide 15: INV103 (ala-Cpn10): overview
INV103 (ala-Cpn10): overview For personal use only > Modified version of natural human protein > Activity ideally suited to the treatment of inflammation associated with autoimmune disease > Data to date > Dose response reduction in biomarkers of inflammation including serum IL-6, MCP1, TNF and IL-1
Slide 16: Phase II clinical program
Phase II clinical program For personal use only Systemic lupus erythematosus (SLE or lupus) > Lupus is a vascular inflammatory disease* > IL-6 is a marker of vascular inflammation, INV103 has a significant effect on IL-6 > Pre-IND meeting with the US FDA: Dec 2012 > FDA confirmed SLE as an important
Slide 17: Summary
Summary For personal use only 2 drug candidates targeting chronic inflammatory diseases − INV102 (nadolol) − INV103 (ala-Cpn10) 3 phase II programs − chronic bronchitis (smoking cessation) − asthma − lupus Large market opportunity Data to support strategy − medical, regulatory, commercial precedent
Slide 18: Invion Limited
For personal use only Invion Limited 2/120 Bluestone Circuit Seventeen Mile Rocks QLD 4073 Australia P: +61 7 3295 0500 F: +61 7 3295 0599 W: www.invion.com.au Contact: investor@invion.com.au